002287 Tibet Cheezheng Tibetan Medicine
- 19.78
- -0.26-1.30%
Tibet Cheezheng Tibetan Medicine News
Express News | Qizheng Tibetan Medicine: Using no more than 1.8 billion idle funds to entrust financial management
Qizheng Tibetan Medicine (002287.SZ): Net profit of 97.468 million yuan in the first quarter increased 5.06% year-on-year
Gelonghui, April 26 | Qizheng Tibetan Pharmaceutical (002287.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 365 million yuan, up 23.37% year on year; net profit attributable to shareholders of listed companies was 97.468 million yuan, up 5.06% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 56.0285 million yuan, an increase of 77.42% year on year; basic earnings per share were 0.1,838 yuan.
Express News | Qizheng Tibetan Medicine: Net profit of 581 million yuan in 2023 increased 22.99% year-on-year, and plans to distribute 10 doses of 4.8 yuan
Qizheng Tibetan Medicine (002287.SZ): As of March 29, 2024, the total number of shareholders of the company was 20,787
Gelonghui, April 1 | Qizheng Tibetan Medicine (002287.SZ) said on an interactive platform that as of March 29, 2024, the total number of shareholders of the company was 20,787.
Qizheng Tibetan Medicine (002287.SZ): As of March 20, 2024, the total number of shareholders of the company was 2,113
Gelonghui March 21丨Qizheng Tibetan Medicine (002287.SZ) said on an interactive platform that as of March 20, 2024, the total number of shareholders of the company was 21,113.
Tianyou German Liquor (002646.SZ): There is no cooperation with Qizheng Tibetan Medicine related to barley wine
Gelonghui March 19 丨 Some investors asked Tianyou Liquor (002646.SZ) on the investor interactive platform, “Do Tianyou Dejiu and Qizheng Tibetan Medicine cooperate on barley wine?” The company replied that there is no cooperation between the company and Qizheng Tibetan Medicine (002287) related to barley wine.
Qizheng Tibetan Medicine (002287.SZ): “Baitai Biologics New Drug Clinical Research Ethane Selenium Project” has been terminated
Gelonghui March 19 丨 Some investors asked Qizheng Tibetan Medicine (002287.SZ) on the investor interactive platform, “In which countries are listed companies' complete vehicles and accessories sold?” The company replied that the company's “Baitai Biotech New Drug Clinical Research Ethane Selenium Project” has been terminated. Anti-cancer drug development has the characteristics of high capital requirements, long cycle time, and relatively high risk. Please pay attention to investment risks.
Qizheng Tibetan Medicine (002287.SZ): As of March 8, 2024, the total number of shareholders of the company was 21,314
Gelonghui March 11 | Qizheng Tibetan Medicine (002287.SZ) said on an interactive platform that as of March 8, 2024, the total number of shareholders of the company was 21,314.
Qizheng Tibetan Medicine (002287.SZ) Performance Report: Net profit of 612 million yuan to the mother in 2023 increased 29.49% year-on-year
On February 22, Gelonghui Tibetan Medicine (002287.SZ) announced its 2023 annual performance report. During the reporting period, the company achieved total revenue of 2,045 billion yuan, an increase of 0.02% over the same period last year. The company achieved operating profit of 648 million yuan, an increase of 24.34% over the same period last year; realized net profit attributable to shareholders of listed companies of 612 million yuan, an increase of 29.49% over the same period of the previous year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of 400 million yuan, a year-on-year decrease of 9.02%; and basic earnings per share of 1.1,549 yuan.
Qizheng Tibetan Medicine (002287.SZ): Qizheng Tibetan Medicine Industry Base Construction Project Completed
Gelonghui, January 8, 丨 Qizheng Tibetan Medicine (002287.SZ) announced that as of December 31, 2023, Tibet Qizheng Tibetan Medicine Co., Ltd. publicly issued convertible corporate bonds to raise capital investment projects, and the overall construction project of the Qizheng Tibetan Medicine Industry Base has reached the scheduled state of use and has met the settlement conditions.
Qizheng Tibetan Medicine (002287.SZ) received a subsidy of 773.14,600 yuan from the Linzhi Investment Promotion Bureau
Qizheng Tibetan Medicine (002287.SZ) issued an announcement. The company recently received incentives from the Linzhi Investment Promotion Bureau...
Qizheng Tibetan Medicine (002287.SZ) released the first three quarter results, net profit of 380 million yuan, up 5.83% year on year
Qizheng Tibetan Pharmaceutical (002287.SZ) released its report for the first three quarters. During the reporting period, the company achieved revenue of 12.4...
Qizheng Tibetan Medicine (002287.SZ): Currently, the company has not included any products in the collection
Glonghui, September 6丨Qizheng Tibetan Medicine (002287.SZ) held a performance briefing on September 6, 2023. “Collection has a great potential impact on stickers. How will the company respond?” The company replied that at present, the company has not included any products in the collection. The company continues to pay attention to the issuance and implementation rules of relevant national policies, and enhances corporate brand competitiveness from management and product aspects. Refine management, strengthen organizational construction, gradually promote the provincial district line management system, activate organizational vitality, and establish a professional independent academic promotion team. Channels are sinking, and the layout and development of county-level hospitals and primary care markets is excellent
Qizheng Tibetan Medicine (002287.SZ): After the Qizheng Tibetan medicine industry base construction project was completed, the company's Qizheng pain relief paste increased production capacity by 80 million pats/year, with a total production capacity of 2
Glonghui, September 6丨Qizheng Tibetan Medicine (002287.SZ) held a performance briefing on September 6, 2023. “After the Lintao new factory is put into operation at the end of the year, can I explain the overall production capacity plan of the listed company for 2024?” The company replied that after the completion of the Qizheng Tibetan medicine industry base construction project, the company added 80 million pats/year for Qizheng pain relief paste, with a total production capacity of 204 million pats/year; increased production capacity of 22 million sticks/year for ointments, with a total production capacity of 39 million sticks/year; a total production capacity of 30,000 pills/year, with a total production capacity of 390 million capsules/year
Qizheng Tibetan Medicine (002287.SZ): Net profit increased by 34.41% in the first half of the year to 312 million yuan
Glonghui, August 24: Qizheng Tibetan Pharmaceutical (002287.SZ) announced its 2023 semi-annual report. Operating income for the reporting period was 829.8 million yuan, down 7.48% year on year; net profit attributable to shareholders of listed companies was 312 million yuan, up 34.41% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 218 million yuan, down 11.32% year on year; basic earnings per share were 0.5893 yuan.
Qizheng Tibetan Medicine: Net profit for the first half of 2023 increased by 48.78% year-on-year
On July 28, GLONGHUI | Qizheng Tibetan Medicine released its semi-annual performance report. During the reporting period, the company achieved total revenue of 920 million yuan, an increase of 2.57% over the same period last year. Among them, the pharmaceutical business increased 2.54% over the same period last year. The company achieved operating profit of 377 million yuan, an increase of 50.15% over the same period last year, and realized net profit attributable to shareholders of listed companies of 346 million yuan, an increase of 48.78% over the same period last year.
Qizheng Tibetan Medicine (002287.SZ) Performance Report: Net profit in the first half of the year increased by 48.78% to 346 million yuan
On July 28丨Qizheng Tibetan Medicine (002287.SZ) announced the 2023 semi-annual results report. During the reporting period, the company achieved operating profit of 377 million yuan, an increase of 50.15% over the same period last year; total profit of 376 million yuan, up 49.60% year on year; net profit attributable to shareholders of listed companies of 346 million yuan, up 48.78% over the same period last year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of 252 million yuan, up 2.24%; basic earnings per share of 0.6523 yuan.
Qizheng Tibetan Medicine (002287.SZ) will distribute a 2022 cash dividend of 3.90 yuan for every 10 shares on July 20
According to the Zhitong Finance App, Qizheng Tibetan Medicine (002287.SZ) announced that the company's 2022 annual equity distribution plan has been reviewed and approved by the company's 2022 annual shareholders' meeting held on May 26, 2023, to pay cash dividends of 3.90 yuan (tax included) to all shareholders. The stock registration date for this equity distribution is July 19, 2023, and the deduction and dividend date is: July 20, 2023. The company has now entrusted China to settle the cash dividends for A-share shareholders of the Shenzhen branch to be distributed through the shareholder escrow securities company (or other custodian agency) on July 20, 2023
Qizheng Tibetan Medicine (002287.SZ): 2022 equity distribution 10 distribution of 3.9 yuan, share registration date July 19
On July 12丨Qizheng Tibetan Medicine (002287.SZ) announced that the company's 2022 annual equity distribution plan is to distribute 3.900,000 yuan in cash (tax included) to all shareholders for every 10 shares based on the total share capital on the day of the company's share registration. The share registration date for this equity distribution is July 19, 2023, and the deduction and interest deduction date is July 20, 2023.
Qizheng Tibetan Medicine (002287.SZ): “Qizheng Tibetan Medicine Industry Base Construction Project” is expected to be completed on December 31, 2023 and put into use one after another
GLONGHUI June 28丨Some investors asked Qizheng Tibetan Medicine (002287.SZ), “How is the construction progress of the company's Lintao production base? Can it be put into production before the end of the year?” Qizheng Tibetan Medicine replied that the company's fund-raising project “Qizheng Tibetan Medicine Industry Base Construction Project” is currently under construction and is expected to be completed on December 31, 2023, and put into use one after another.
Analysis
Price Target
No Data
